FDA shifts COVID-19 vaccine approval policies to focus on high-risk individuals, will demand more robust data for low-risk individuals. US to move away from one-size-fits-all approach. Trust in scientific community has declined.
Key Points
FDA to approve vaccines for high-risk individuals
Stricter scientific analysis for low-risk individuals
US aligning policies with European nations
Pros
Focus on high-risk individuals for vaccine approval
Demanding more robust data for low-risk individuals